New combo therapy aims to boost platelets in immune disorder
NCT ID NCT07278908
First seen Jan 10, 2026 · Last updated May 12, 2026 · Updated 15 times
Summary
This study tests whether adding all-trans retinoic acid to avatrombopag works better than avatrombopag alone for adults with immune thrombocytopenia (ITP) who didn't improve with first treatment. About 248 participants will take the drugs for up to 24 weeks, then taper off, and be followed for a year. The goal is to see if more people can stop treatment and maintain safe platelet levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ITP - IMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.